Solengepras delivers positive ARISE Phase 3 results as Cerevance prepares for FDA talks
Cerevance’s solengepras cuts Parkinson’s OFF time and improves daily motor function in a positive Phase 3 trial ahead of FDA discussions.
Features & Analysis